Insider trade

Director sold ~$5.43M of JAZZ shares in the open market

Traded Nov 26, 2025 · Filed Dec 2, 2025

Why it stands out

A board member of Jazz Pharmaceuticals sold $5.43M of Jazz Pharmaceuticals shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$1M+

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$5,428,567

Shares × reported transaction price

Timing vs results

21 days after results of Nov 5, 2025, 47 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−2.7%	+0.2%	−2.9%
30 days	+3.9%	+0.2%	+3.6%
90 days	+14.3%	+0.7%	+13.5%
180 days	+39.5%	+11.3%	+28.3%

Past results only. Not a forecast.

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $177.70 to $178.685. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Officer sold

10mo ago

Jazz Pharmaceuticals's SVP, Technical Operations sold $379K of Jazz Pharmaceuticals shares. Nobody planned it ahead of time.

10mo ago

Routine share withholding; mechanical by default.

Automatic sale10mo ago